Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 232

1.

CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls.

Weischer M, Bojesen SE, Ellervik C, Tybjaerg-Hansen A, Nordestgaard BG.

J Clin Oncol. 2008 Feb 1;26(4):542-8. doi: 10.1200/JCO.2007.12.5922. Epub 2008 Jan 2. Review.

PMID:
18172190
[PubMed - indexed for MEDLINE]
2.

CHEK2*1100delC homozygosity is associated with a high breast cancer risk in women.

Adank MA, Jonker MA, Kluijt I, van Mil SE, Oldenburg RA, Mooi WJ, Hogervorst FB, van den Ouweland AM, Gille JJ, Schmidt MK, van der Vaart AW, Meijers-Heijboer H, Waisfisz Q.

J Med Genet. 2011 Dec;48(12):860-3. doi: 10.1136/jmedgenet-2011-100380. Epub 2011 Nov 5.

PMID:
22058428
[PubMed - indexed for MEDLINE]
3.

Increased risk of breast cancer associated with CHEK2*1100delC.

Weischer M, Bojesen SE, Tybjaerg-Hansen A, Axelsson CK, Nordestgaard BG.

J Clin Oncol. 2007 Jan 1;25(1):57-63. Epub 2006 Jul 31.

PMID:
16880452
[PubMed - indexed for MEDLINE]
4.

[CHEK2 c.1100delC may not contribute to genetic background of hereditary breast cancer from Shanghai of China].

Song CG, Hu Z, Yuan WT, Di GH, Shen ZZ, Huang W, Shao ZM.

Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2006 Aug;23(4):443-5. Chinese.

PMID:
16883537
[PubMed - indexed for MEDLINE]
5.

German populations with infrequent CHEK2*1100delC and minor associations with early-onset and familial breast cancer.

Rashid MU, Jakubowska A, Justenhoven C, Harth V, Pesch B, Baisch C, Pierl CB, Brüning T, Ko Y, Benner A, Wichmann HE, Brauch H, Hamann U; GENICA Network.

Eur J Cancer. 2005 Dec;41(18):2896-903. Epub 2005 Oct 18.

PMID:
16239104
[PubMed - indexed for MEDLINE]
6.

The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families.

Oldenburg RA, Kroeze-Jansema K, Kraan J, Morreau H, Klijn JG, Hoogerbrugge N, Ligtenberg MJ, van Asperen CJ, Vasen HF, Meijers C, Meijers-Heijboer H, de Bock TH, Cornelisse CJ, Devilee P.

Cancer Res. 2003 Dec 1;63(23):8153-7.

PMID:
14678969
[PubMed - indexed for MEDLINE]
Free Article
7.

Excess breast cancer risk in first degree relatives of CHEK2∗1100delC positive familial breast cancer cases.

Adank MA, Verhoef S, Oldenburg RA, Schmidt MK, Hooning MJ, Martens JW, Broeks A, Rookus M, Waisfisz Q, Witte BI, Jonker MA, Meijers-Heijboer H.

Eur J Cancer. 2013 May;49(8):1993-9. doi: 10.1016/j.ejca.2013.01.009. Epub 2013 Feb 14.

PMID:
23415889
[PubMed - indexed for MEDLINE]
8.

CHEK2 1100delC variant and breast cancer risk in Caucasians: a meta-analysis based on 25 studies with 29,154 cases and 37,064 controls.

Yang Y, Zhang F, Wang Y, Liu SC.

Asian Pac J Cancer Prev. 2012;13(7):3501-5.

PMID:
22994785
[PubMed - indexed for MEDLINE]
Free Article
9.

CHEK2 1100delC and male breast cancer in the Netherlands.

Wasielewski M, den Bakker MA, van den Ouweland A, Meijer-van Gelder ME, Portengen H, Klijn JG, Meijers-Heijboer H, Foekens JA, Schutte M.

Breast Cancer Res Treat. 2009 Jul;116(2):397-400. doi: 10.1007/s10549-008-0162-7. Epub 2008 Aug 31.

PMID:
18759107
[PubMed - indexed for MEDLINE]
10.

The CHEK2 1100delC mutation is not present in Korean patients with breast cancer cases tested for BRCA1 and BRCA2 mutation.

Choi DH, Cho DY, Lee MH, Park HS, Ahn SH, Son BH, Haffty BG.

Breast Cancer Res Treat. 2008 Dec;112(3):569-73. doi: 10.1007/s10549-007-9878-z. Epub 2008 Jan 3.

PMID:
18175216
[PubMed - indexed for MEDLINE]
11.

Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts.

Bell DW, Kim SH, Godwin AK, Schiripo TA, Harris PL, Haserlat SM, Wahrer DC, Haiman CA, Daly MB, Niendorf KB, Smith MR, Sgroi DC, Garber JE, Olopade OI, Le Marchand L, Henderson BE, Altshuler D, Haber DA, Freedman ML.

Int J Cancer. 2007 Dec 15;121(12):2661-7.

PMID:
17721994
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Age at onset of bilateral breast cancer, the presence of hereditary BRCA1, BRCA2, CHEK2 gene mutations and positive family history of cancer.

Skasko E, Kluska A, Niwińska A, Kwiatkowska E, Bałabas A, Piatkowska M, Dabrowska M, Nowakowska D, Pieńkowski T.

Onkologie. 2009 Apr;32(4):182-8. doi: 10.1159/000200930. Epub 2009 Mar 13.

PMID:
19372713
[PubMed - indexed for MEDLINE]
13.

Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation.

Schmidt MK, Tollenaar RA, de Kemp SR, Broeks A, Cornelisse CJ, Smit VT, Peterse JL, van Leeuwen FE, Van't Veer LJ.

J Clin Oncol. 2007 Jan 1;25(1):64-9. Epub 2006 Nov 28.

PMID:
17132695
[PubMed - indexed for MEDLINE]
14.

The contribution of founder mutations to early-onset breast cancer in French-Canadian women.

Ghadirian P, Robidoux A, Zhang P, Royer R, Akbari M, Zhang S, Fafard E, Costa M, Martin G, Potvin C, Patocskai E, Larouche N, Younan R, Nassif E, Giroux S, Narod SA, Rousseau F, Foulkes WD.

Clin Genet. 2009 Nov;76(5):421-6. doi: 10.1111/j.1399-0004.2009.01277.x.

PMID:
19863560
[PubMed - indexed for MEDLINE]
15.

Gene expression profiling assigns CHEK2 1100delC breast cancers to the luminal intrinsic subtypes.

Nagel JH, Peeters JK, Smid M, Sieuwerts AM, Wasielewski M, de Weerd V, Trapman-Jansen AM, van den Ouweland A, Brüggenwirth H, van I Jcken WF, Klijn JG, van der Spek PJ, Foekens JA, Martens JW, Schutte M, Meijers-Heijboer H.

Breast Cancer Res Treat. 2012 Apr;132(2):439-48. doi: 10.1007/s10549-011-1588-x. Epub 2011 May 26.

PMID:
21614566
[PubMed - indexed for MEDLINE]
16.

CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies.

CHEK2 Breast Cancer Case-Control Consortium.

Am J Hum Genet. 2004 Jun;74(6):1175-82. Epub 2004 Apr 30.

PMID:
15122511
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Effect of CHEK2 missense variant I157T on the risk of breast cancer in carriers of other CHEK2 or BRCA1 mutations.

Cybulski C, Górski B, Huzarski T, Byrski T, Gronwald J, Debniak T, Wokolorczyk D, Jakubowska A, Serrano-Fernández P, Dork T, Narod SA, Lubinski J.

J Med Genet. 2009 Feb;46(2):132-5. doi: 10.1136/jmg.2008.061697. Epub 2008 Oct 17.

PMID:
18930998
[PubMed - indexed for MEDLINE]
18.

Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.

Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, Higgins J, Roach KC, Mandell J, Lee MK, Ciernikova S, Foretova L, Soucek P, King MC.

JAMA. 2006 Mar 22;295(12):1379-88.

PMID:
16551709
[PubMed - indexed for MEDLINE]
19.

Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations.

Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, Hollestelle A, Houben M, Crepin E, van Veghel-Plandsoen M, Elstrodt F, van Duijn C, Bartels C, Meijers C, Schutte M, McGuffog L, Thompson D, Easton D, Sodha N, Seal S, Barfoot R, Mangion J, Chang-Claude J, Eccles D, Eeles R, Evans DG, Houlston R, Murday V, Narod S, Peretz T, Peto J, Phelan C, Zhang HX, Szabo C, Devilee P, Goldgar D, Futreal PA, Nathanson KL, Weber B, Rahman N, Stratton MR; CHEK2-Breast Cancer Consortium.

Nat Genet. 2002 May;31(1):55-9. Epub 2002 Apr 22.

PMID:
11967536
[PubMed - indexed for MEDLINE]
20.

Family history, genetic testing, and clinical risk prediction: pooled analysis of CHEK2 1100delC in 1,828 bilateral breast cancers and 7,030 controls.

Fletcher O, Johnson N, Dos Santos Silva I, Kilpivaara O, Aittomäki K, Blomqvist C, Nevanlinna H, Wasielewski M, Meijers-Heijerboer H, Broeks A, Schmidt MK, Van't Veer LJ, Bremer M, Dörk T, Chekmariova EV, Sokolenko AP, Imyanitov EN, Hamann U, Rashid MU, Brauch H, Justenhoven C, Ashworth A, Peto J.

Cancer Epidemiol Biomarkers Prev. 2009 Jan;18(1):230-4. doi: 10.1158/1055-9965.EPI-08-0416.

PMID:
19124502
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk